Table 3.
Imatinib resistance characteristics in Iranian CML patients
| Author(s) /Year | Type of resistance |
Phases in mutated patients
(no.) |
Detection methods | Name of evaluated genes | T315I mutation assessment | Frequency of mutation site in BCR/ABL domain (% £ )>10% | Gene mutation frequency(% £ ) >10% |
Patients mutation frequency
% ⱡ |
|---|---|---|---|---|---|---|---|---|
| Rejali L, et al./2015 (30)a |
Secondary | AP (3) CP (1) |
PCR-RFLP, DS | G250E L384M Y253H V379I |
NA | P-loop (75) Between C- domain and A-loop (25). |
G250E (25) L384M (25) Y253H (25) V379I (25) |
10.25 |
| Rostami G, et al./2015 (38) | Primary Secondary |
CP (3) | DS | E355G G398R |
No mutation was observed | C-domain (66.66) A-loop (33.33) |
E355G (66.66) G398R (33.33) |
13.63 |
| Abbasian S, et al./2015 (42) | NA | NA | Real time-PCR | SIRT1 expression | NA | NA | NA | NA |
| Chahardouli B, et al. /2013 (23) | NA | AP (2) BP (2) |
ASO-RT-PCR ,BDS |
T315I | Mutation was observed | Drug-binding site | NA | 7 |
| Chahardouli B, et al./2013 (24) | NA | CP (21) AP (3) BP (8) |
BDS | G250E, T315I M244V, F359C E255K, M351T F359V, E459G Y253H, E255V D276N, E279A F317L, E355G L387M, L387F H396R, S438C E453A |
Mutation was observed | Drug-binding site (29) P-loop (26) C-terminal (12) |
G250E (14.7) T315I (11.8) |
29.1 |
| Solali S, et al./2013 (29) |
NA | NA | SYBER-Green Real-time RT-PCR | hOCT1 MDR1 |
NA | NA | NA | NA |
| Chahardouli B, et al./2019 (18) | NA | NA | Real-time PCR | STAT3 expression | NA | NA | NA | NA |
a
The reported data in this article were ambiguous and confusing.
£
number of gene mutations/total mutations*100, ⱡ number of mutated patients/total resistant patients*100, NA; not available or not applicable, AP; accelerated phase, BP; blastic phase, CP; chronic phase, PCR; polymerase chain reaction, RFLP; restriction fragment length polymorphism, RT; reverse transcription, ASO; allele-specific oligonucleotide, DS; direct sequencing, BDS; bidirectional sequencing, hOCT1; human organic cation transporter, MDR1; multi-drug resistance 1, P-loop; phosphate-binding loop, A-loop; activation loop, C-terminal; carboxyl-terminal, C-domain; catalytic domain